Skip to main content

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting · Phase 3 · NCT04928846

Conditions: Non Small Cell Lung Cancer, c-MET

At a glance

Research payments reported, 2025
$942,069
U.S. investigators named
38
Sites paid
34
Planned or actual enrollment
768

About the trial

Sponsor
AbbVie
Tested
Telisotuzumab Vedotin (biological), Docetaxel (drug)
Dates
Started 2022-03-25; completion 2029-02
Results posted
Not yet

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group…

From ClinicalTrials.gov, last updated 2026-10-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $942,069 in research payments for this study in 2025 (223 payments).

Products named: Emrelis

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.